Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Raised by HighTower Advisors LLC

Key Points

• HighTower Advisors LLC increased its stake in Arrowhead Pharmaceuticals by 49.8% during the 1st quarter, now holding 112,417 shares valued at approximately $1.43 million.
• Insider James C. Hamilton sold 9,389 shares at an average price of $20.00, reducing his stake by 3.46% and retaining around 262,122 shares valued at about $5.24 million.
• Analysts have mixed ratings on Arrowhead Pharmaceuticals, with two analysts rating it as a strong buy and others issuing hold or neutral ratings, with an average target price of $43.14.

HighTower Advisors LLC boosted its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 49.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,417 shares of the biotechnology company's stock after buying an additional 37,361 shares during the quarter. HighTower Advisors LLC owned 0.08% of Arrowhead Pharmaceuticals worth $1,432,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 1,628 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at about $49,000. CWM LLC grew its position in shares of Arrowhead Pharmaceuticals by 134.3% during the 1st quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock valued at $56,000 after buying an additional 2,523 shares during the last quarter. KBC Group NV grew its position in shares of Arrowhead Pharmaceuticals by 40.8% during the 1st quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after buying an additional 2,132 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the 1st quarter valued at about $133,000. Institutional investors and hedge funds own 62.61% of the company's stock.

Insider Buying and Selling

In related news, insider James C. Hamilton sold 9,389 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $20.00, for a total transaction of $187,780.00. Following the completion of the sale, the insider directly owned 262,122 shares of the company's stock, valued at $5,242,440. This represents a 3.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. B. Riley raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, August 11th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, May 20th. Wall Street Zen cut shares of Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. TD Cowen upgraded shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Finally, Chardan Capital restated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock traded down $0.31 on Friday, hitting $22.03. The company had a trading volume of 2,388,669 shares, compared to its average volume of 2,433,496. The business has a 50-day simple moving average of $17.71 and a 200-day simple moving average of $16.00. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. The company has a market cap of $3.05 billion, a PE ratio of -17.21 and a beta of 0.94. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $27.34.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to analyst estimates of $29.01 million. During the same period in the previous year, the business earned ($1.38) EPS. Research analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.